In the FGFR1-amplified cell line MDA-MB-134, treatment with an anti-FGFR1 antibody reduced the phosphorylation of FRS2 and ERK1/2 downstream of the receptor, which resulted in the reduction of tumour growth in pre-clinical models [179]. Here, FGFR1 is linked to neoplasm.